Fulcrum Therapeutics, Inc.
FULCNASDAQHealthcare● Active
$3.44
$-0.25(-6.78%)
Market Cap$186143140
P/E Ratio—
52W High$15.74
52W Low$2.83
Fulcrum Therapeutics, Inc. (FULC) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
FULC · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: Apr 27, 2026EPS Actual
-$0.25
Est. -$0.31 · +19.4%
Revenue
—
Fiscal Period
Q2 FY2026
FY ends December
Report Date
Apr 27, 2026
After Market Close
▲ Beat EPS✓ 2-Quarter EPS Beat Streak
FULC reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 4, 2026 | -$0.22 | — | — | — | — | — |
| ▲ Q2 FY2026 | Apr 27, 2026 | -$0.31 | -$0.25 | +19.4% | — | — | — |
| — Q1 FY2026 | Feb 24, 2026 | -$0.31 | -$0.31 | +0.0% | — | — | — |
| ▼ Q4 FY2025 | Oct 29, 2025 | -$0.29 | -$0.31 | -6.9% | — | — | — |
| ▲ Q3 FY2025 | Jul 29, 2025 | -$0.29 | -$0.28 | +3.5% | — | — | — |
| ▲ Q2 FY2025 | May 1, 2025 | -$0.29 | -$0.28 | +3.5% | — | — | — |
| ▼ Q1 FY2025 | Feb 25, 2025 | -$0.28 | -$0.31 | -10.7% | — | — | — |
| ▲ Q4 FY2024 | Nov 13, 2024 | -$0.40 | -$0.35 | +12.5% | — | — | — |
Q3 FY2026
Aug 4, 2026
EPS Actual
—
EPS Est.
-$0.22
EPS Surpr.
—
Revenue
—
Q2 FY2026
Apr 27, 2026Beat
EPS Actual
-$0.25
EPS Est.
-$0.31
EPS Surpr.
+19.4%
Revenue
—
Q1 FY2026
Feb 24, 2026
EPS Actual
-$0.31
EPS Est.
-$0.31
EPS Surpr.
+0.0%
Revenue
—
Q4 FY2025
Oct 29, 2025Miss
EPS Actual
-$0.31
EPS Est.
-$0.29
EPS Surpr.
-6.9%
Revenue
—
Q3 FY2025
Jul 29, 2025Beat
EPS Actual
-$0.28
EPS Est.
-$0.29
EPS Surpr.
+3.5%
Revenue
—
Q2 FY2025
May 1, 2025Beat
EPS Actual
-$0.28
EPS Est.
-$0.29
EPS Surpr.
+3.5%
Revenue
—
Q1 FY2025
Feb 25, 2025Miss
EPS Actual
-$0.31
EPS Est.
-$0.28
EPS Surpr.
-10.7%
Revenue
—
Q4 FY2024
Nov 13, 2024Beat
EPS Actual
-$0.35
EPS Est.
-$0.40
EPS Surpr.
+12.5%
Revenue
—
Analyst Estimates
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $-0.28 | $-0.28 | $-0.28 | 6 |
| Q3 FY2027 | $-0.28 | $-0.28 | $-0.28 | 3 |
| Q2 FY2027 | $-0.28 | $-0.28 | $-0.28 | 5 |
| Q1 FY2027 | $-0.28 | $-0.28 | $-0.28 | 3 |
| Q4 FY2026 | $-0.17 | $-0.17 | $-0.17 | 6 |
| Q3 FY2026 | $-0.26 | $-0.17 | $-0.05 | 8 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | Apr 27, 2026 | +19.4% | $7.84 | $7.72 | -1.53% |
| ▲ Q1 FY2026 | Feb 24, 2026 | +0.0% | $10.89 | $8.58 | -21.21% |
| ▼ Q4 FY2025 | Oct 29, 2025 | -6.9% | $10.00 | $9.36 | -6.40% |
| ▲ Q3 FY2025 | Jul 29, 2025 | +3.5% | $7.81 | $7.59 | -2.82% |
| ▲ Q2 FY2025 | May 1, 2025 | +3.5% | $3.85 | $4.38 | +13.77% |
| ▼ Q1 FY2025 | Feb 25, 2025 | -10.7% | $3.70 | $3.70 | +0.00% |
| ▲ Q4 FY2024 | Nov 13, 2024 | +12.5% | $3.64 | $3.56 | -2.20% |
| ▲ Q3 FY2024 | Jul 31, 2024 | +7060.5% | $8.41 | $9.28 | +10.34% |
Q2 FY2026-1.53%
Report Date
Apr 27, 2026
EPS Beat/Miss
+19.4%
Price Before
$7.84
Price After
$7.72
Q1 FY2026-21.21%
Report Date
Feb 24, 2026
EPS Beat/Miss
+0.0%
Price Before
$10.89
Price After
$8.58
Q4 FY2025-6.40%
Report Date
Oct 29, 2025
EPS Beat/Miss
-6.9%
Price Before
$10.00
Price After
$9.36
Q3 FY2025-2.82%
Report Date
Jul 29, 2025
EPS Beat/Miss
+3.5%
Price Before
$7.81
Price After
$7.59
Q2 FY2025+13.77%
Report Date
May 1, 2025
EPS Beat/Miss
+3.5%
Price Before
$3.85
Price After
$4.38
Q1 FY2025+0.00%
Report Date
Feb 25, 2025
EPS Beat/Miss
-10.7%
Price Before
$3.70
Price After
$3.70
Q4 FY2024-2.20%
Report Date
Nov 13, 2024
EPS Beat/Miss
+12.5%
Price Before
$3.64
Price After
$3.56
Q3 FY2024+10.34%
Report Date
Jul 31, 2024
EPS Beat/Miss
+7060.5%
Price Before
$8.41
Price After
$9.28
Avg Beat Reaction-0.61%
Avg Miss Reaction-3.20%
Beat Rate6 / 8 quarters
Largest Move-21.21% (Q1 FY2026)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: FULC ends December
Fulcrum Therapeutics, Inc. (FULC) most recently reported earnings on April 27, 2026 for Q2 FY2026, posting EPS of $-0.25 — beating the analyst consensus of $-0.31 by +19.4%. FULC has beaten EPS estimates for 2 consecutive quarters. The next FULC earnings date is expected around September 1, 2026.
Each quarter, investors track FULC earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. FULC revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
FULC's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
FULC earnings · 5 questionsFulcrum Therapeutics, Inc.'s next earnings report is expected around September 1, 2026. FULC typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; FULC historically reports after market close (AMC).
FULC earnings datewhen is FULC earningsFULC next earnings datewhen does FULC report earningsFULC earnings calendar
▸ Source: FMP · Fulcrum Therapeutics, Inc. SEC filings · US GAAP · Fulcrum Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026